NEW YORK (
) hit a new 52-week low Thursday as it traded at $3.16 compared with its previous 52-Week low of $3.18. Allos is changing hands at $3.16 with 21,765 shares traded as of 9:35 a.m. ET. Average volume has been 1.3 million shares over the past 30 days.
Allos has a market cap of $344.5 million and is part of the
industry. Shares are down 30.6% year to date as of the close of trading on Wednesday.
Allos Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing anti-cancer therapeutics.
TheStreet Ratings rates Allos as sell. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself and deteriorating net income. You can view the full
or get investment ideas from our